

FY25 EU (Spain only) PCBCR data in line with Chapter 10a of Directive 2013/34/EU

Section 1

Name of the ultimate parent of the group	Gilead Sciences Inc.
Country where the ultimate parent has its registered office	United States
Financial year- start date	1 January 2025
Financial year- end date	31 December 2025
Reporting currency	USD
Is the information in the report based on reporting instructions used for tax purposes, pursuant to Section III, Parts Band C, and Annex III to Directive 2011/6/EU (yes/no)?	Yes

Section 2¹

Tax jurisdiction	Country code	Revenues	Profit (loss) before income tax	Income tax paid- on cash basis	Income tax accrued- current year	Accumulated earnings	Number of employees
Spain	ES	657,311,063	16,763,691	4,926,732	5,951,866	167,940,671	258

Section 3

Member state or tax jurisdiction	Country code	Name of each subsidiary undertaking in the Member State or tax jurisdiction	Brief description of the nature of activities in the Member State or tax jurisdiction
Spain	ES	<ul style="list-style-type: none"> • Gilead Sciences, S.L. 	<ul style="list-style-type: none"> • Distribution and marketing of pharmaceutical products.

¹ Our PCBCR data has been sourced primarily from our US GAAP consolidation reporting systems.

Section 4

The data set out above is published on behalf of Gilead Sciences, S.L. 28033 Madrid, Parque Empresarial Cristalia, Edif 7/8, Via de los Poblados, 3, Spain to meet the Public Country by Country Reporting requirements as required in Spain by the Eleventh Additional Provision ("11th AP") of Law 22/2015.

It is approved by the Directors of Gilead Sciences, S.L. It is anticipated that this publication will be superseded by the publication of a full Gilead EU Country by Country Report on income tax information as required by Chapter 10a of Directive 2013/34/EU.

Publication of the Spanish only data is provided initially due to the accelerated 6 month reporting timetable in Spain. The information to prepare a full EU Country by Country Report on income tax was not made available to Gilead Sciences, S.L. within this accelerated timeframe as the preparation, review and approval process for the full Gilead EU Country by Country Report is aligned with the standard 12 month reporting timetable set out in the Directive.